Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a French national trial, conducted using a double-blind, placebo-controlled, randomised design involving 7 centers and 80 patients of both sexes.

The primary objective of the trial is to evaluate the effects of the interruption of a long term treatment (ex. Greater than 6 months) with Amantadine (prescribed as an antidyskinetic) in patients suffering from Parkinson disease being treated with Levodopa and suffering from mid dose dyskinesias.

Secondary objectives of the trial are the evaluation of the other effects of withdrawal of Amantadine on the same group of patients: motor fluctuations, vigilance, apathy, fatigue, certain cognitive aspects, the disappearance or development of undesirable side effects and quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease

NCT01538329

Parkinson Disease

COMPLETED PHASE2

The Effect of Amantadine as add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial

NCT06817200

Parkinson Disease (PD)

NOT_YET_RECRUITING PHASE2

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

NCT02153632

Parkinson's Disease Levodopa Induced Dyskinesia (LID)

TERMINATED PHASE3

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

NCT02153645

Parkinson's Disease Levodopa Induced Dyskinesias (LID)

TERMINATED PHASE3

Is Long-term Use of Amantadine Effective in PD?

NCT04260581

Parkinson Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial will involve the participation of the patients for a period of 3 months each. The two groups of patients to be studied are:

* a group who will continue their treatment with Amantadine with no modification to dosage;
* a group who will have their dosage of Amantadine progressively replaced over several days with a placebo (with the aim of avoiding a "brutal" withdrawal which has been associated with symptoms of hyperthermia in rare cases in the literature).

The trial visits are scheduled as such:

* weekly visits for the first 4 weeks, with a telephone call between each visit to assure that the withdrawal from Amantadine causes any problems.
* every 2 weeks from week 4 until week 8, with weekly telephone calls in between these visits.
* a telephone call in the 10th week followed by an end of study visit in week 12. In the event of an early withdrawal from the trial, and assuming that the patient gives their consent, a complete end of study visit will be performed prior to recommencing open label treatment with Amantadine in progressively increasing doses (100mg every 3 days until the pre-study dose is reached).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Amantadine MANTADIX

Group Type ACTIVE_COMPARATOR

mantadix

Intervention Type DRUG

dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).

2

placebo

Group Type PLACEBO_COMPARATOR

mantadix

Intervention Type DRUG

dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mantadix

dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female or Male Patients with Idiopathic Parkinson's disease
* Presenting peak dose dyskinesias under levodopa therapy
* Patient receiving Amantadine for dyskinesia at a dose greater or equal to 200 mg/day (minimum dose at which one can observe anti dyskinetic effects) for at least 6 months.
* Patients between 30 and 80 years of age
* Patients having reported a subjective amelioration in their dyskinesias under Amantadine (at the beginning of their treatment with same)
* Patient with a Mini- Mental State Exam score \> 24
* Patient not presenting a cognitive problem that could impair the comprehension of the patient and their participation in the protocol (patient diaries)
* Receiving an anti-parkinsonian treatment at a stable dose for at least 2 months with the expectation that the treatment will remain unchanged throughout the course of the patients participation in the trial.
* Signed informed consent obtained
* Patient eligible for social security (specific requirement under french law)

Exclusion Criteria

* Atypical parkinsonian syndrome (progressive supranuclear palsy, multi-system atrophy, etc)

* Patient with parkinsonian syndrome secondary to medication
* Patients presenting with dyskinesias whose severity allow an insufficient margin for observing any aggravation which follows a potential withdrawal of treatment (UPDRS 32+33 \>6)
* Patients receiving treatment with Apokinon© injector pens (unless that treatment enters into a therapeutic schema at fixed hours)
* Patient presenting with dementia or an evolving dopaminergic psychosis
* Patient receiving neuroleptics or anticholinesterases
* Patients having received functional surgery for their Parkinsons' Disease
* Patients pregnant or at risk of same
* Patients who are: wards of the state requirement under french law).

Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No